The DMTN Knockout AGS Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population generated through targeted disruption of the human DMTN gene in the AGS gastric adenocarcinoma epithelial cell line. This loss-of-function model facilitates investigation of dematin, an actin-binding and bundling protein critical for cytoskeletal organization and membrane skeleton integrity. The polyclonal knockout population provides a heterogeneous genetic background, reflecting a broad spectrum of editing events and enabling robust functional studies without the clonal variability associated with monoclonal isolates.
The host AGS cell line, derived from a human gastric adenocarcinoma (ATCC CRL-1739), exhibits adherent epithelial morphology and is a well-established in vitro model for gastric cancer pathogenesis and pharmacological testing. AGS cells retain key signaling pathways relevant to tumorigenesis, including those governing proliferation, adhesion, and metabolic reprogramming. Their utility in drug sensitivity assays and mechanistic cancer research makes them an ideal platform for exploring the molecular consequences of DMTN disruption within a context that closely mimics the human disease state.
Dematin, encoded by DMTN, functions as a central organizer of the spectrin?Cactin membrane skeleton, primarily through its interactions with spectrin, actin, protein 4.1R, adducin, and calmodulin. It is regulated upstream by cAMP-dependent protein kinase (PKA) and protein kinase C (PKC) signaling, which modulate its phosphorylation state and binding affinities. Downstream, dematin influences the trafficking and function of GLUT1, the facilitative glucose transporter, thereby affecting cellular glucose uptake. Additionally, dematin promotes integrin-mediated adhesion sites, linking mechanical cues to cytoskeletal remodeling. Knockout of DMTN disrupts these multiprotein complexes, leading to destabilization of the spectrin-based network and altered actin dynamics.
In the context of AGS gastric adenocarcinoma cells, DMTN ablation impairs cell adhesion, shape maintenance, and migration, while potentially dysregulating GLUT1-dependent glucose transport. These perturbations extend to downstream signaling pathways implicated in cancer progression, including those governing epithelial-to-mesenchymal transition and metabolic adaptation. Therefore, the DMTN Knockout AGS Polyclonal Cells serve as a powerful system to dissect how loss of dematin contributes to gastric tumor invasiveness, altered glucose metabolism, and cytoskeletal reorganization, providing insights into hereditary spherocytosis and anemia where dematin mutations are pathogenic.
Typical research applications include functional interrogation of DMTN in gastric cancer through western blotting, immunofluorescence, and co-immunoprecipitation to assess protein interactions. The model is suitable for quantitative cell migration and invasion studies using wound healing and transwell assays, as well as for glucose uptake measurements. Flow cytometry and RNA sequencing can profile phenotypic and transcriptomic changes. Drug sensitivity testing against standard chemotherapeutics may reveal dematin-dependent vulnerabilities. For detailed product specifications or technical guidance, please contact Ascent Research.
